{"id":30617,"date":"2022-06-19T18:40:00","date_gmt":"2022-06-19T10:40:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30617"},"modified":"2025-03-26T18:43:19","modified_gmt":"2025-03-26T10:43:19","slug":"shanghai-pharmaceuticals-licenses-benapenem-and-plazomicin-from-xuanzhu-bio-for-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30617","title":{"rendered":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China"},"content":{"rendered":"\n

China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607<\/a>, SHA: 601607<\/a>) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio\u2019s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).<\/p>\n\n\n\n

Deal Financials<\/strong>
The total deal value for benapenem is RMB 266 million (USD 39.7 million), while plazomicin is valued at RMB 174 million (USD 26 million). Upfront payments are RMB 14 million (USD 2.08 million) for benapenem and RMB 7 million (USD 1.04 million) for plazomicin. Shanghai Pharma will become the exclusive Marketing Authorization Holder (MAH) for both drugs in the region.<\/p>\n\n\n\n

Drug Profiles<\/strong>
Benapenem is a Category 1.1 carbapenem antibiotic that inhibits bacterial cell wall synthesis by acting on penicillin binding proteins (PBPs), leading to bacterial death. It has completed a Phase II clinical study in China for complicated urinary tract infections, meeting clinical endpoints.<\/p>\n\n\n\n

Plazomicin, a new-generation aminoglycoside derivative, works by inhibiting bacterial protein synthesis through binding to the 30S subunit of bacterial ribosomes. The drug received US marketing approval in 2018 for treating last-line complicated urinary tract infections caused by multi-drug-resistant Enterobacteriaceae.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[890,891,196,670],"class_list":["post-30617","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals","tag-xuanzhu-biopharmaceutical"],"yoast_head":"\nShanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio\u2019s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30617\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30617\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-19T10:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T10:43:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China\",\"datePublished\":\"2022-06-19T10:40:00+00:00\",\"dateModified\":\"2025-03-26T10:43:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617\"},\"wordCount\":200,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30617#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30617\",\"name\":\"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-19T10:40:00+00:00\",\"dateModified\":\"2025-03-26T10:43:19+00:00\",\"description\":\"China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio\u2019s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30617\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30617#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China - Insight, China's Pharmaceutical Industry","description":"China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio\u2019s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30617","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30617","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-19T10:40:00+00:00","article_modified_time":"2025-03-26T10:43:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30617#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30617"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China","datePublished":"2022-06-19T10:40:00+00:00","dateModified":"2025-03-26T10:43:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30617"},"wordCount":200,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30617#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30617","url":"https:\/\/flcube.com\/?p=30617","name":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-19T10:40:00+00:00","dateModified":"2025-03-26T10:43:19+00:00","description":"China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot firm Xuanzhu Biopharmaceutical Co., Ltd. Under the terms, Shanghai Pharma secures exclusive rights (including sub-licensing, manufacturing, development, and sales) to Xuanzhu Bio\u2019s benapenem and plazomicin in Greater China (mainland China, Hong Kong, Macau, and Taiwan).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30617#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30617"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30617#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30617"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30617\/revisions"}],"predecessor-version":[{"id":30618,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30617\/revisions\/30618"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}